SPP1 and hepatocellular carcinoma: A 2023 study reported the presence of SPP1-expressing TAM in alpha-fetoprotein-positive HCC tissues and demonstrated that SPP1 can inhibit the anti-cancer activity of T cells by binding to CD44 [40].